To read the full article for free, please click here.
Affected heavily by recent technological advancements, the sector may soon attract Chinese regulators' attention.
2021 turned out to become a positive year for China's healthcare industry, where the gigantic demand stems from the aging population, growing individual wealth, and – more importantly – the COVID-19 crisis' aftermath. The market has grown consistently; in 2020, the growth rate slumped to 7.2% due to the massive lockdowns, although it is expected to rise back to 17.6% in 2021 with total market size of CNY 8.7 trillion. Despite this, the market remains relatively undeveloped – since 2016, the Chinese authorities have been working on creating a CNY 16 trillion healthcare ecosystem by 2030.
Online healthcare is in the limelight
The pandemic challenged people's sense of well-being and facilitated their desire and determination to become more active and engaged in managing their health, which also boosted the need for remote medical consultations and online medicine sales. According to Deloitte, the portion of consumers who have used virtual visits rose from 15% to 19% from 2019 to early 2020, then jumped to 28% in April 2020. In fact, consumers plan to continue using them – 80% of the Deloitte survey respondents are likely to keep using other online services even post COVID-19.
Jessica Tan, co-CEO of Ping An Group, once said that around 20% to 25% of healthcare services in China could be moved to the online space. This will present new opportunities to the most competitive businesses in this field. Among these, JD Health (6618:HK) and Alibaba Health (0241:HK) are two tech giant-backed companies that have ridden this surging wave quite well.
Alibaba (BABA:NASDAQ) is deemed to be the first explorer among Chinese tech giants, having joined the game as early as 1998 by founding Alibaba Health (0241:HK). In fact, it is the first Chinese Internet-healthcare company to go public on the Hong Kong Stock Exchange. Alibaba Health is primarily engaged in the pharmaceutical direct sales business, the pharmaceutical e-commerce platform business, medical and healthcare services platforms and digital infrastructure business and related services, though it wants to take off the 'e-pharmacy' tag for long.
And the latecomer, JD Health, is moving really fast – only four months' independent operation since May 2019 before it filed a public offering. In August 2020, JD Health ranked 35th on Hurun Global Unicorn Index 2020 with a valuation at CNY 50 billion, which crowned it as the world's youngest unicorn. Different from traditional platforms, JD Health has established various online and offline integrated businesses, including JD Pharmacy, JD Health Internet Hospital and Pharmacy Alliance.
Check out our previous article about Alibaba Health and JD Health:
How do Alibaba and JD.com compare in their healthcare endeavors?
In September 2021, JD Health released its interim financial report with relatively strong results. Its total revenue increased by over half (55.4%), from CNY 8.8 billion in H1 2020 to CNY 13.6 billion in H1 2021, which was primarily due to the increase in revenue from sales of pharmaceutical and healthcare products within the reporting period. In fact, this continuous upward trend also shows in its gross profit for the past four fiscal years, although the loss enlarged even further in 2020 when compared with the previous years. Another catalyst for the growth could be the increase in JD Health's number of Annual Active User (AAU) accounts. As of June 30, 2021, the AAUs in the past 12 months reached 109 million, representing a net addition of over 18.8 million as compared with that of 2020. The growing number also shows that the stickiness of users has been well improved as well as its brand awareness. In other words, JD Health's constant investment in marketing activities – its selling and marketing expenses almost doubled for two consecutive fiscal years – finally began to work.
Alibaba Health finally became fully profitable in its fiscal 2021, when the revenue reached CNY 15.52 billion Among four major businesses, medicine remains the main contributor to its revenue, amounting to CNY 13.21 billion, or about 85% of the total revenue. The rest is contributed by pharmaceutical e-commerce platform business, the medical health service business and digital infrastructure business, with revenues of CNY 1.96 billion, CNY 284 million and CNY 53 million respectively. Benefiting from the improving cost control ability and the emerging economies of scale, the overall expenses of Alibaba Health are far less than that of JD Health for every comparable fiscal year.
BABA's backing is the ace card of Alibaba Health
As the healthcare business arm of Alibaba Group, the natural traffic comes with related brand benefits; Alibaba Health's core pharmaceutical direct sales and e-commerce platform businesses are thus boosted to a great extent. Three specific edges are worth mentioning.
First, brand power drives growth. In 2021, Alibaba has grown its brand value by 32% year-on-year to USD 201.86 billion, with a 2nd ranking domestically and 7th ranking globally. As one of the most valuable brands, consumers are more likely to pay a value premium for the products with this recognizable name, or for the creditability it owns. This is indeed what is going on with Alibaba Health. For the 12 months ended March 31, 2021, the revenue from drugs generated from the pharmaceutical direct sales business under the brand of 'Alibaba Health' increased by 86.1% year-on-year, accounting for 64.8% of the revenue of the business. And the number of annual active users of the direct online stores in the reporting period reached a record high of 81 million.
Second, synergistic benefits of Alibaba's ecosystem. The synergy effect is most difficult or even impossible to be imitated by competitors...
To read the full article for free, please click here.